image
Healthcare - Medical - Devices - NASDAQ - US
$ 1.25
-5.26 %
$ 16.7 M
Market Cap
-1.52
P/E
1. INTRINSIC VALUE

This DCF valuation model was last updated on May, 7, 2025.

The intrinsic value of one NXL stock under the worst case scenario is HIDDEN Compared to the current market price of 1.25 USD, Nexalin Technology, Inc. is HIDDEN

This DCF valuation model was last updated on May, 7, 2025.

The intrinsic value of one NXL stock under the base case scenario is HIDDEN Compared to the current market price of 1.25 USD, Nexalin Technology, Inc. is HIDDEN

This DCF valuation model was last updated on May, 7, 2025.

The intrinsic value of one NXL stock under the best case scenario is HIDDEN Compared to the current market price of 1.25 USD, Nexalin Technology, Inc. is HIDDEN

2. FUNDAMENTAL ANALYSIS

Price Chart NXL

image
$4.5$4.5$4.0$4.0$3.5$3.5$3.0$3.0$2.5$2.5$2.0$2.0$1.5$1.5$1.0$1.015 Nov15 NovDec '24Dec '2415 Dec15 DecJan '25Jan '2515 Jan15 JanFeb '25Feb '2515 Feb15 FebMar '25Mar '2515 Mar15 MarApr '25Apr '2515 Apr15 AprMay '25May '25
FINANCIALS
169 K REVENUE
52.35%
-7.75 M OPERATING INCOME
-36.13%
-7.61 M NET INCOME
-63.64%
-3.94 M OPERATING CASH FLOW
-2.84%
-578 K INVESTING CASH FLOW
-12.97%
4.52 M FINANCING CASH FLOW
2358.09%
27.2 K REVENUE
-24.57%
-2.88 M OPERATING INCOME
-14.63%
-2.83 M NET INCOME
-15.73%
-1.13 M OPERATING CASH FLOW
-41.77%
1.63 M INVESTING CASH FLOW
136.30%
0 FINANCING CASH FLOW
0.00%
Balance Sheet Nexalin Technology, Inc.
image
Current Assets 3.96 M
Cash & Short-Term Investments 3.48 M
Receivables 13 K
Other Current Assets 468 K
Non-Current Assets 262 K
Long-Term Investments 864
PP&E 0
Other Non-Current Assets 261 K
82.41 %11.09 %6.17 %Total Assets$4.2m
Current Liabilities 547 K
Accounts Payable 156 K
Short-Term Debt 0
Other Current Liabilities 391 K
Non-Current Liabilities 0
Long-Term Debt 0
Other Non-Current Liabilities 0
28.53 %71.47 %Total Liabilities$546.7k
EFFICIENCY
Earnings Waterfall Nexalin Technology, Inc.
image
Revenue 169 K
Cost Of Revenue 36.6 K
Gross Profit 132 K
Operating Expenses 7.85 M
Operating Income -7.75 M
Other Expenses -147 K
Net Income -7.61 M
1m1m00(1m)(1m)(2m)(2m)(3m)(3m)(4m)(4m)(5m)(5m)(6m)(6m)(7m)(7m)(8m)(8m)169k(37k)132k(8m)(8m)147k(8m)RevenueRevenueCost Of RevenueCost Of RevenueGross ProfitGross ProfitOperating ExpensesOperating ExpensesOperating IncomeOperating IncomeOther ExpensesOther ExpensesNet IncomeNet Income
RATIOS
78.31% GROSS MARGIN
78.31%
-4596.14% OPERATING MARGIN
-4596.14%
-4508.73% NET MARGIN
-4508.73%
-206.94% ROE
-206.94%
-180.15% ROA
-180.15%
-210.82% ROIC
-210.82%
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis Nexalin Technology, Inc.
image
00(500k)(500k)(1m)(1m)(1m)(1m)(2m)(2m)(2m)(2m)(3m)(3m)(3m)(3m)(4m)(4m)(4m)(4m)202020202021202120222022202320232024202420252025
Net Income -7.61 M
Depreciation & Amortization 15.1 K
Capital Expenditures 0
Stock-Based Compensation 3.56 M
Change in Working Capital 122 K
Others 113 K
Free Cash Flow -4.11 M
3. WALL STREET ANALYSTS ESTIMATES
Wall Street Analysts Price Targets Nexalin Technology, Inc.
image
NXL has no price targets from Wall Street.
4. DIVIDEND ANALYSIS
5. COMPETITION
slide 2 of 10
6. Ownership
Insider Ownership Nexalin Technology, Inc.
image
Sold
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
0 USD 0
Bought
13.2 K USD 1
0-3 MONTHS
17.8 K USD 1
3-6 MONTHS
248 K USD 2
6-9 MONTHS
5.77 K USD 1
9-12 MONTHS
7. News
Nexalin Technology Announces Closing of Previously Announced $5.0 Million Underwritten Public Offering HOUSTON, May 06, 2025 (GLOBE NEWSWIRE) --  Nexalin Technology, Inc. (Nasdaq: NXL; NXLIW) (the “Company” or “Nexalin”), the leader in Deep Intracranial Frequency Stimulation (DIFS™) of the brain, today announced the closing of its previously announced underwritten public offering of 3,850,000 shares of its common stock at a public offering price of $1.30 per share. The gross proceeds from the offering to Nexalin were approximately $5.0 million, before deducting underwriting discounts and commissions and other offering expenses. globenewswire.com - 1 week ago
Nexalin Technology Announces Pricing of $5.0 Million Public Offering of Common Stock HOUSTON, May 05, 2025 (GLOBE NEWSWIRE) -- Nexalin Technology, Inc. (Nasdaq: NXL; NXLIW) (the “Company” or “Nexalin”), the leader in Deep Intracranial Frequency Stimulation (DIFS™) of the brain, today announced the pricing of an underwritten public offering of 3,850,000 shares of its common stock at a price to the public of $1.30 per share. The gross proceeds from the offering to Nexalin are expected to be approximately $5.0 million, before deducting underwriting discounts and commissions and other offering expenses. The offering is expected to close on or about May 6, 2025, subject to customary closing conditions. In addition, Nexalin has granted the underwriters a 45-day option to purchase up to 577,500 additional shares of common stock at the public offering price, less the underwriting discounts and commissions. globenewswire.com - 2 weeks ago
Nexalin Technology Initiates FDA Q-Submission Process for Gen-2 SYNC Following Encouraging Data and Preliminary FDA Feedback Company initiates formal regulatory engagement on trial design for Alzheimer's, dementia, and MCI indications Company initiates formal regulatory engagement on trial design for Alzheimer's, dementia, and MCI indications globenewswire.com - 2 weeks ago
Nexalin Technology Receives IRB Approval in Brazil and Begins Clinical Trial for Anxiety and Insomnia HOUSTON, TX, April 24, 2025 (GLOBE NEWSWIRE) -- Nexalin Technology, Inc. (Nasdaq: NXL; NXLIW) (the “Company” or “Nexalin”) the leader in Deep Intracranial Frequency Stimulation (DIFS™) of the brain, today announced that its proprietary Gen-2 neurostimulation device has received institutional review board (IRB) approval in Brazil for a new clinical trial evaluating its use in the treatment of anxiety disorders and chronic insomnia. The study will be conducted at the Instituto de Psiquiatria do Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo (IPq-HCFMUSP), one of Latin America's most prestigious psychiatric research institutions. globenewswire.com - 3 weeks ago
Nexalin Technology Announces Completion of Phases One Through Five of its Virtual Clinic and Digital Ecosystem for HALO™ Clinical Research and Patient Management AI-Powered Platform Now Fully Operational to Support Data Capture, Remote Monitoring, and Virtual Treatment with HALO™ AI-Powered Platform Now Fully Operational to Support Data Capture, Remote Monitoring, and Virtual Treatment with HALO™ globenewswire.com - 3 weeks ago
Nexalin Technology Expresses Strong Support for Health Tech Investment Act to Advance Medicare Reimbursement for AI-Enabled Devices HOUSTON, TX, April 21, 2025 (GLOBE NEWSWIRE) -- Nexalin Technology, Inc. (Nasdaq: NXL; NXLIW) (the “Company” or “Nexalin”) the leader in Deep Intracranial Frequency Stimulation (DIFS™) of the brain, today announced its support for the Health Tech Investment Act (S. 1399) — bipartisan legislation introduced in the United States Senate that would expand Medicare reimbursement opportunities for FDA-cleared or approved medical devices that incorporate artificial intelligence (AI) or machine learning. globenewswire.com - 4 weeks ago
Nexalin Technology Secures USPTO Patent for Deep Intracranial Frequency Stimulation (DIFS™) Technology in Treating Substance Use Disorders Patent Approval Reinforces Nexalin's Leadership in Non-Invasive Brain Stimulation for Addiction Treatment Patent Approval Reinforces Nexalin's Leadership in Non-Invasive Brain Stimulation for Addiction Treatment globenewswire.com - 1 month ago
Nexalin Technology Enrolls First Patients and Advances Toward Treatment in UCSD Clinical Trial HOUSTON, TX, April 02, 2025 (GLOBE NEWSWIRE) -- Nexalin Technology, Inc. (Nasdaq: NXL; NXLIW) (the “Company” or “Nexalin”) the leader in Deep Intracranial Frequency Stimulation (DIFS™) of the brain, today announced that it has successfully enrolled the first patients in its clinical trial at the University of California, San Diego (UCSD), in collaboration with the VA San Diego Healthcare System (San Diego VA). The company began treatment of the first patients this week with the Nexalin HALO™. globenewswire.com - 1 month ago
Join Nexalin Technology's Exclusive Live Investor Webinar and Q&A Session on April 3 Houston, TX, March 26, 2025 (GLOBE NEWSWIRE) -- Nexalin Technology, Inc. (Nasdaq: NXL; NXLIW) (the “Company” or “Nexalin”) is pleased to invite investors to a webinar on April 3, 2025, at 4:15 p.m. ET. globenewswire.com - 1 month ago
Nexalin Technology Receives Notice of Allowance from the USPTO for Patent Covering Deep Intracranial Frequency Stimulation (DIFS™) Technology for Opioid and Other Substance Use Disorders Patent Strengthens Nexalin's Intellectual Property Portfolio and Highlights the Potential of DIFS™ Technology in Addressing Substance Use Disorders, Including Opioids, Alcohol, Cocaine and Methamphetamine Patent Strengthens Nexalin's Intellectual Property Portfolio and Highlights the Potential of DIFS™ Technology in Addressing Substance Use Disorders, Including Opioids, Alcohol, Cocaine and Methamphetamine globenewswire.com - 2 months ago
Nexalin Technology Announces Initiation of Patient Recruitment for UCSD's TBI & PTSD Clinical Study Following IRB Approval HALO™ Clarity Devices Successfully Shipped for First Phase of Clinical Trials HALO™ Clarity Devices Successfully Shipped for First Phase of Clinical Trials globenewswire.com - 2 months ago
Nexalin Technology Welcomes General Wesley Clark to Military & Government Advisory Board HOUSTON, TX, Feb. 26, 2025 (GLOBE NEWSWIRE) -- Nexalin Technology, Inc. (Nasdaq: NXL; NXLIW) (the “Company” or “Nexalin”) the leader in Deep Intracranial Frequency Stimulation (DIFS™) of the brain, is honored to announce that General Wesley K. Clark (Ret.), former NATO Supreme Allied Commander Europe, has joined its Military & Government Advisory Board. General Clark will collaborate with esteemed members David F. Lasseter, former Deputy Assistant Secretary of Defense for Policy, and William A. Hudson, Jr., former Acting General Counsel to the Department of Veterans Affairs, to advance Nexalin's innovative neurostimulation solutions within U.S. military and government sectors. The Company's on-going “Nexalin America” initiative includes addressing post-traumatic stress disorder, traumatic brain injury, substance use disorder, and other areas of significant concern to the U.S. government. globenewswire.com - 2 months ago
8. Profile Summary

Nexalin Technology, Inc. NXL

image
COUNTRY US
INDUSTRY Medical - Devices
MARKET CAP $ 16.7 M
Dividend Yield 0.00%
Description Nexalin Technology, Inc., a medical device company, designs and develops neurostimulation products for the treatment of mental health in the United States and China. It licenses and markets Nexalin Device, a non-invasive and drug-free therapy for the treatment of anxiety and insomnia. The company's Nexalin device emits a patented frequency-based waveform, which stimulates a positive response from the mid-brain structures associated with various mental health disorders. It also engages in the development of Generation 2, a medical device that is in clinical trials for the treatment of substance abuse issues related to opiates, chronic pain, Alzheimer's disease, and dementia. The company was incorporated in 2021 and is headquartered in Houston, Texas.
Contact 1776 Yorktown, Houston, TX, 77056 https://www.nexalin.com
IPO Date Sept. 16, 2022
Employees 6
Officers Ms. Marilyn Elson Controller Dr. David Owens M.D. Chief Medical Officer & Director Mr. Mark White President, Chief Executive Officer, Chief Financial Officer & Director Ms. Carolyn Shelton Executive Vice President of Clinical, Quality & Regulatory Affairs and Chief Operating Officer Mr. John Patrick Claude Co-Founder and Director of Engineering & Development